ArticleMedicine2020

IDO, TDO, and AHR overexpression is associated with poor outcome in diffuse large B-cell lymphoma patients in the rituximab era.

Xiangli Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.